Breast cancer breakthrough

September 20, 2015

However Dr. Witkiewicz pointed out, ???In patients older than 65 years, there was no difference in survival between patients with low and high IGF-1R expression??But in patients younger than 65, those with high IGF-1R expression had longer survival than those with low expression.??? The longest survival was seen in younger patients with high IGF-1R expression, and the poorest survival was seen in older patients (>55 years) with low IGF-1R expression. She added, ???For now, we know that it is there and we know it is a marker of better prognosis??The next step is to learn if triple-negative breast cancer patients benefit from targeting IGF-1R.???

Program chair Gordon B. Mills from the Department of Systems Biology at the University of Texas M.D. Anderson Cancer Center, in Houston said, ?????we have developed a pathway to the development of molecular diagnostics and biomarkers??Importantly, we have a much better concept of the limitations, challenges, and hurdles that need to be overcome for the implementation of molecular diagnostics.???

This latest research was presented at the 4th American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development, in Denver, Colorado.

In a separate finding, Australian researchers were able to identify specific targets for future breast cancer treatments. They used the latest protein screening technology to profile basal breast cancer. Dr Falko Hochgr?fe and Professor Roger Daly of Sydney's Garvan Institute of Medical Research studied protein behavior in basal breast cancer through a process known as phosphorylation.